ASMB — Assembly Biosciences Balance Sheet
0.000.00%
- $108.30m
- -$3.78m
- $28.52m
Annual balance sheet for Assembly Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 216 | 147 | 91.6 | 130 | 112 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.23 | 0.336 | 0.944 | 0.043 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 224 | 154 | 97 | 134 | 116 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10.7 | 7.18 | 3.94 | 2.72 | 3.35 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 283 | 191 | 102 | 137 | 119 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 24.4 | 16.1 | 16.3 | 39.2 | 47.8 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 42.7 | 22.1 | 19.1 | 95.7 | 85.8 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Total Equity | 241 | 169 | 82.7 | 41.1 | 33.4 |
Total Liabilities & Shareholders' Equity | 283 | 191 | 102 | 137 | 119 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |